Articles by Marion R. Munk, MD, PhD

The Retina TL;DR with Dr. Weng: Unpacking photobiomodulation for dry AMD with Drs. Do, Lad, and Munk
ByChristina Y. Weng, MD, MBA, FASRS,Diana V. Do, MD, Eleonora (Nora) M. Lad, MD, PhD,Marion R. Munk, MD, PhD In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Drs. Do, Lad, and Munk about the LIGHTSITE III trial data behind photobiomodulation and what it means for retina practice.

ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.